BioSpace News Archive

Cadrenal Therapeutics, Inc. announced that it has closed its previously announced private placement with an institutional investor for the issuance and sale of 4,285,715 of its shares of common stock at a purchase price of $1.75 per share priced at-the-market under Nasdaq rules.

Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) (“ALPA”) today announced the successful completion of its business combination (the “Business Combination”) with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications (“Carmell”).

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) today announced that members of its management team will host an investor call on Monday, July 17 at 8:00 am ET to share topline results from the Phase 3 ATTRibute-CM clinical study in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Seres Therapeutics, Inc. today announced that on July 13, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 66,066 shares of its common stock to seven new employees.

Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets.

Stevanato Group S.p.A. announced today that it will issue financial results for the second quarter of 2023 on Friday, July 28, 2023, at 6:30 a.m. (ET).

Intellipharmaceutics International Inc. today reported the results of operations for the three and six months ended May 31, 2023.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes.

Cryo-Cell International, Inc., the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023.